• The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

  • Jan 30 2025
  • Duración: 27 m
  • Podcast

The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • We love to hear from our listeners. Send us a message.

    Helen Sabzevari, Ph.D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors. These vectors offer significant advantages in delivering large genetic payloads, a crucial factor in developing effective gene therapies. Sabzevari also discusses Precigen's recent BLA submission for PRGN-2012, which includes Phase 1/2 pivotal study results where over 50% of patients achieved Complete Response and more than 85% experienced decreased surgical interventions.

    Subscribe to the podcast!
    Apple | Spotify | YouTube
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles